429 related articles for article (PubMed ID: 30974033)
81. Usefulness of Glucagon-Like Peptide-1 Receptor Agonists to Reduce Adverse Cardiovascular Disease Events in Patients with Type 2 Diabetes Mellitus.
Grewal S; Zaman N; Borgatta L; Nudy M; Foy AJ; Peterson B
Am J Cardiol; 2021 Sep; 154():48-53. PubMed ID: 34266665
[TBL] [Abstract][Full Text] [Related]
82. Glucagon-like peptide-1 (GLP-1) receptor agonists in type 2 diabetes and long-term complications: FOCUS on retinopathy.
Marchand L; Luyton C; Bernard A
Diabet Med; 2021 Jan; 38(1):e14390. PubMed ID: 32799379
[No Abstract] [Full Text] [Related]
83. Gastrointestinal adverse events of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a systematic review and network meta-analysis.
Sun F; Chai S; Yu K; Quan X; Yang Z; Wu S; Zhang Y; Ji L; Wang J; Shi L
Diabetes Technol Ther; 2015 Jan; 17(1):35-42. PubMed ID: 25375397
[TBL] [Abstract][Full Text] [Related]
84. Risk of Anaphylaxis Among New Users of GLP-1 Receptor Agonists: A Cohort Study.
Anthony MS; Aroda VR; Parlett LE; Djebarri L; Berreghis S; Calingaert B; Beachler DC; Crowe CL; Johannes CB; Juhaeri J; Lanes S; Pan C; Rothman KJ; Saltus CW; Walsh KE
Diabetes Care; 2024 Apr; 47(4):712-719. PubMed ID: 38363873
[TBL] [Abstract][Full Text] [Related]
85. Cardiovascular benefits of GLP-1 agonists in type 2 diabetes: a comparative review.
Boyle JG; Livingstone R; Petrie JR
Clin Sci (Lond); 2018 Aug; 132(15):1699-1709. PubMed ID: 30115742
[TBL] [Abstract][Full Text] [Related]
86. Cardiovascular efficacy and safety of sodium-glucose co-transporter-2 inhibitors and glucagon-like peptide-1 receptor agonists: a systematic review and network meta-analysis.
Hussein H; Zaccardi F; Khunti K; Seidu S; Davies MJ; Gray LJ
Diabet Med; 2019 Apr; 36(4):444-452. PubMed ID: 30653708
[TBL] [Abstract][Full Text] [Related]
87. A review of GLP-1 receptor agonists: Evolution and advancement, through the lens of randomised controlled trials.
Aroda VR
Diabetes Obes Metab; 2018 Feb; 20 Suppl 1():22-33. PubMed ID: 29364586
[TBL] [Abstract][Full Text] [Related]
88. GLP-1 receptor agonists for prevention of cardiorenal outcomes in type 2 diabetes: An updated meta-analysis including the REWIND and PIONEER 6 trials.
Giugliano D; Maiorino MI; Bellastella G; Longo M; Chiodini P; Esposito K
Diabetes Obes Metab; 2019 Nov; 21(11):2576-2580. PubMed ID: 31373167
[TBL] [Abstract][Full Text] [Related]
89. Efficacy of GLP-1rA, liraglutide, in plaque psoriasis treatment with type 2 diabetes: a systematic review and meta-analysis of prospective cohort and before-after studies.
Chang G; Chen B; Zhang L
J Dermatolog Treat; 2022 May; 33(3):1299-1305. PubMed ID: 33934692
[TBL] [Abstract][Full Text] [Related]
90. Do GLP-1 Receptor Agonists Increase the Risk of Breast Cancer? A Systematic Review and Meta-analysis.
Piccoli GF; Mesquita LA; Stein C; Aziz M; Zoldan M; Degobi NAH; Spiazzi BF; Lopes Junior GL; Colpani V; Gerchman F
J Clin Endocrinol Metab; 2021 Mar; 106(3):912-921. PubMed ID: 33248445
[TBL] [Abstract][Full Text] [Related]
91. Clinical Outcomes with GLP-1 Receptor Agonists in Patients with Heart Failure: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
Zhao H; Liu Y; Liu M; Xu Y; Ling Q; Lin W; Zhang J; Yan Z; Ma J; Li W; Zhao Y; Yu P; Liu X; Wang J
Drugs; 2023 Sep; 83(14):1293-1307. PubMed ID: 37639180
[TBL] [Abstract][Full Text] [Related]
92. Translating results from the cardiovascular outcomes trials with glucagon-like peptide-1 receptor agonists into clinical practice: Recommendations from a Eastern and Southern Europe diabetes expert group.
Janez A; Muzurovic E; Stoian AP; Haluzik M; Guja C; Czupryniak L; Duvnjak L; Lalic N; Tankova T; Bogdanski P; Papanas N; Nunes JS; Kempler P; Fras Z; Rizzo M
Int J Cardiol; 2022 Oct; 365():8-18. PubMed ID: 35905827
[TBL] [Abstract][Full Text] [Related]
93. Effect of liraglutide on blood pressure: a meta-analysis of liraglutide randomized controlled trials.
Zhao X; Huang K; Zheng M; Duan J
BMC Endocr Disord; 2019 Jan; 19(1):4. PubMed ID: 30616638
[TBL] [Abstract][Full Text] [Related]
94. Glucagon-Like Peptide-1 Receptor Agonist (GLP-1RA) Therapy Adherence for Patients with Type 2 Diabetes in a Medicare Population.
Nguyen H; Dufour R; Caldwell-Tarr A
Adv Ther; 2017 Mar; 34(3):658-673. PubMed ID: 28078541
[TBL] [Abstract][Full Text] [Related]
95. The effect of glucagon-like peptide 1 and glucagon-like peptide 1 receptor agonists on energy expenditure: A systematic review and meta-analysis.
Maciel MG; Beserra BTS; Oliveira FCB; Ribeiro CM; Coelho MS; Neves FAR; Amato AA
Diabetes Res Clin Pract; 2018 Aug; 142():222-235. PubMed ID: 29857094
[TBL] [Abstract][Full Text] [Related]
96. Comparative efficacy of glucagon-like peptide 1 (GLP-1) receptor agonists, pioglitazone and vitamin E for liver histology among patients with nonalcoholic fatty liver disease: systematic review and pilot network meta-analysis of randomized controlled trials.
Gu Y; Sun L; He Y; Yang L; Deng C; Zhou R; Kong T; Zhang W; Chen Y; Li J; Shi J
Expert Rev Gastroenterol Hepatol; 2023 Mar; 17(3):273-282. PubMed ID: 36689199
[TBL] [Abstract][Full Text] [Related]
97. Effect of glucagon-like peptide-1 receptor agonists in subjects with type 2 diabetes mellitus: A meta-analysis.
Qian W; Liu F; Yang Q
J Clin Pharm Ther; 2021 Dec; 46(6):1650-1658. PubMed ID: 34355405
[TBL] [Abstract][Full Text] [Related]
98. The association between glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and suicidality: reports to the Food and Drug Administration Adverse Event Reporting System (FAERS).
McIntyre RS; Mansur RB; Rosenblat JD; Kwan ATH
Expert Opin Drug Saf; 2024 Jan; 23(1):47-55. PubMed ID: 38087976
[TBL] [Abstract][Full Text] [Related]
99. Comparison of Characteristics Between Chinese Patients Taking Glucagon-like Peptide 1 Receptor Agonists and Insulin: A Cross-sectional Database Analysis.
Wang K; Chen Y; Strizek A; Boye K; Gu L; Liu Y; Qu S
Clin Ther; 2019 Oct; 41(10):2057-2065. PubMed ID: 31514971
[TBL] [Abstract][Full Text] [Related]
100. GLP-1RAs caused gastrointestinal adverse reactions of drug withdrawal: a system review and network meta-analysis.
Zhang Z; Zhang Q; Tan Y; Chen Y; Zhou X; Liu S; Yu J
Front Endocrinol (Lausanne); 2023; 14():1149328. PubMed ID: 37484944
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
